Search All Tech Briefings

Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available. Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 1139 Results

Clear All Filters

Title	Intervention	Indication	Therapeutic Area	Year	Actions
Pembrolizumab for Hepatocellular Carcinoma – Adjuvant	Pembrolizumab (Keytruda; MK-3475)	Hepatocellular carcinoma (HCC)	Gastrointestinal Cancer	2021	View \| Download
Pembrolizumab for recurrent or metastatic nasopharyngeal cancer	Pembrolizumab (Keytruda; MK-3475)	Nasopharyngeal cancer	Head and Neck Cancer	2021	View \| Download
Pembrolizumab for renal cell carcinoma - adjuvant therapy post nephrectomy	Pembrolizumab (Keytruda; MK-3475)	Renal cell carcinoma (RCC)	Renal Cancer	2020	View \| Download
Pembrolizumab for Stage IV Colorectal Carcinoma – first line	Pembrolizumab (Keytruda; MK-3475)	Colorectal cancer	Gastrointestinal Cancer , Oncology	2018	View \| Download
Pembrolizumab for treatment of solid tumours – second line	Pembrolizumab (Keytruda; MK-3475)	Solid tumours	Haematological Cancer and Lymphomas , Oncology	2021	View \| Download
Pembrolizumab in addition to chemotherapy for advanced or metastatic urothelial cancer - first line	Pembrolizumab (Keytruda; MK-3475)	Urothelial cancer	Urological Cancer	2018	View \| Download
Pembrolizumab in addition to Chemotherapy for Locally Advanced, Non-Metastatic Triple Negative Breast Cancer – neoadjuvant, first line	Pembrolizumab (Keytruda; MK-3475)	Breast cancer	Breast Cancer	2018	View \| Download
Pembrolizumab in addition to chemotherapy for locally recurrent, inoperable or metastatic triple-negative breast cancer - first line	Pembrolizumab (Keytruda; MK-3475)	Breast cancer	Breast Cancer	2018	View \| Download
Pembrolizumab in addition to chemotherapy for perioperative treatment of gastric or gastro-oesophageal junction adenocarcinoma	FLOT , Pembrolizumab (Keytruda; MK-3475)	Gastric cancer , Gastro-oesophageal junction cancer	Gastrointestinal Cancer	2019	View \| Download
Pembrolizumab in addition to cisplatin and fluorouracil for recurrent locally advanced or metastatic oesophageal cancer – First-line	5-Fluorouracil , Cisplatin (Platinol) , Pembrolizumab (Keytruda; MK-3475)	Oesophageal cancer	Head and Neck Cancer	2019	View \| Download